HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Current status of new drug development for inflammatory bowel diseases].

AuthorsYutaka Kohgo, Hiroki Tanabe, Mikihiro Fujiya
JournalNihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 70 Suppl 1 Pg. 378-82 (Feb 2012) ISSN: 0047-1852 [Print] Japan
PMID23126121 (Publication Type: Journal Article)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin Fab Fragments
  • Natalizumab
  • Steroids
  • Polyethylene Glycols
  • Mesalamine
  • golimumab
  • vedolizumab
  • Infliximab
  • Ustekinumab
  • Adalimumab
  • tocilizumab
  • Certolizumab Pegol
Topics
  • Adalimumab
  • Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Certolizumab Pegol
  • Humans
  • Immunoglobulin Fab Fragments (therapeutic use)
  • Inflammatory Bowel Diseases (drug therapy)
  • Infliximab
  • Mesalamine (therapeutic use)
  • Natalizumab
  • Polyethylene Glycols (therapeutic use)
  • Steroids (therapeutic use)
  • Ustekinumab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: